On August 12, 2020 Atomwise Inc., which uses artificial intelligence to help academic and commercial scientists discover new medicines, reported that it has raised $123 million to expand and build its own pipeline of experimental drugs (Press release, Atomwise, AUG 12, 2020, View Source [SID1234563442]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Based in San Francisco, Atomwise is one of several startups seeking to use AI to speed drug development and uncover medicines that would be difficult to discover through other means. Others include Deep Genomics Inc., which in January said it had raised $40 million to develop treatments for conditions such as the rare disorder.